Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: BLD036
MIFTS: 52

Bile Duct Disease

Categories: Liver diseases, Gastrointestinal diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Bile Duct Disease

About this section

MalaCards integrated aliases for Bile Duct Disease:

Name: Bile Duct Disease 12 14
Bile Duct Diseases 40 41 69
Bile Duct Disorder Nos 12
Disorder of Bile Duct 12

Classifications:

MalaCards categories:
Anatomical: Liver diseases Gastrointestinal diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:4138
MeSH 41 D001649
NCIt 46 C96716
SNOMED-CT 64 118926004 197455006
UMLS 69 C0005395
Sources

Summaries for Bile Duct Disease

About this section
MedlinePlus : 40 Your liver makes a digestive juice called bile. Your gallbladder stores it between meals. When you eat, your gallbladder pushes the bile into tubes called bile ducts. They carry the bile to your small intestine. The bile helps break down fat. It also helps the liver get rid of toxins and wastes. Different diseases can block the bile ducts and cause a problem with the flow of bile: Gallstones, which can increase pressure in the gallbladder and cause a gallbladder attack. The pain usually lasts from one to several hours. Cancer Infections Birth defects, such as biliary atresia. It is the most common reason for liver transplants in children in the United States. Inflammation, which can cause scarring. Over time, this can lead to liver failure. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Bile Duct Disease, also known as bile duct diseases, is related to common bile duct disease and cholangitis, and has symptoms including gastrointestinal gas, nausea and vomiting and icterus. An important gene associated with Bile Duct Disease is GPT (Glutamic--Pyruvic Transaminase), and among its related pathways/superpathways are Metabolism and Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds. The drugs Vancomycin and Etomidate have been mentioned in the context of this disorder. Affiliated tissues include liver, lung and kidney, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 72 A bile duct is any of a number of long tube-like structures that carry bile, and is present in most... more...

Sources

Related Diseases for Bile Duct Disease

About this section

Diseases related to Bile Duct Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 48)
# Related Disease Score Top Affiliating Genes
1 common bile duct disease 33.6 CCK GGT2
2 cholangitis 32.1 ABCB11 ABCB4 ALB GGT1 GPT
3 sclerosing cholangitis 30.4 ABCB11 ABCB4 ALB NR1I2
4 cholangitis, primary sclerosing 30.2 ABCB4 GGT1 GPT NR1I2
5 caroli disease 11.0
6 cholestasis, benign recurrent intrahepatic, 1 10.5 ABCB11 ATP8B1
7 cholestasis, progressive familial intrahepatic, 2 10.5 ABCB11 ABCB4 ATP8B1
8 atp8b1 deficiency 10.5 ABCB11 ATP8B1 NR1H4
9 cholestasis, progressive familial intrahepatic, 3 10.5 ABCB11 ABCB4 ATP8B1
10 choledocholithiasis 10.4 ABCB4 ALB GPT
11 kwashiorkor 10.4 ALB GPT
12 hepatic encephalopathy 10.4 ALB GPT SLC25A13
13 hyperbilirubinemia, rotor type 10.4 ABCC2 ALB
14 paralytic ileus 10.4 ALB CCK
15 xanthomatosis 10.3 CYP7A1 NR1H4 NR1I2
16 cerebrotendinous xanthomatosis 10.3 CYP7A1 NR1H4 NR1I2
17 cyclosporiasis 10.3 GGT1 GGT2
18 autoimmune disease of urogenital tract 10.3 ABCB4 ALB GGT2
19 algoneurodystrophy 10.3 GGT1 GGT2
20 dubin-johnson syndrome 10.3 ABCC2 ABCC3 ABCC4
21 cholecystitis 10.3 ABCB4 ALB CCK GPT
22 periampullary adenoma 10.3 GGT1 GGT2
23 viral hepatitis 10.2 ALB GGT1 GPT
24 obstructive jaundice 10.2 ALB GGT1 GPT SLC25A13
25 bilirubin metabolic disorder 10.2 ABCC2 ALB GGT1 GPT
26 ethmoid sinus cancer 10.1 GGT1 GGT2
27 hepatitis b 10.1 ALB GGT1 GPT SLC10A1
28 leber congenital amaurosis 10.1 ABCB11 CYP7A1 NR1H4 NR1I2
29 biliary atresia 10.1 ALB GPT NR1H4 SLC10A1 SLC10A2
30 hepatic tuberculosis 10.1 ALB GGT1 GGT2 GPT
31 ethmoid sinus adenocarcinoma 10.1 GGT1 GGT2
32 hepatic coma 10.1 ALB GPT
33 cholelithiasis 10.0 ABCB4 ALB CCK CYP7A1 GPT NR1H4
34 cholestasis, progressive familial intrahepatic, 1 9.9 ABCB11 ABCB4 ATP8B1 GGT1 NR1H4 SLC10A2
35 cataract 5, multiple types 9.7
36 fibrosis of extraocular muscles, congenital, 1 9.7
37 cystic fibrosis 9.7
38 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 9.7
39 cholangiocarcinoma 9.7
40 echinococcosis 9.7
41 intrahepatic cholangiocarcinoma 9.7
42 gastrointestinal system disease 9.7 ABCB11 ALB CCK GGT1 GGT2 NR1I2
43 extrahepatic cholestasis 9.7 ABCB4 ABCC2 ABCC3 CYP7A1 GGT1 GPT
44 liver disease 9.7 ABCB11 ABCB4 ALB ATP8B1 GGT1 GPT
45 primary biliary cirrhosis 9.5 ABCB11 ABCB4 ABCC2 ABCC3 ALB GGT1
46 intrahepatic cholestasis 8.9 ABCB11 ABCB4 ABCC2 ABCC3 ALB ATP8B1
47 cholestasis 8.6 ABCB11 ABCB4 ABCC2 ABCC3 ABCC4 ATP8B1
48 biliary tract disease 7.4 ABCB11 ABCB4 ABCC2 ABCC3 ABCC4 ALB

Graphical network of the top 20 diseases related to Bile Duct Disease:



Diseases related to Bile Duct Disease
Sources

Symptoms & Phenotypes for Bile Duct Disease

About this section

UMLS symptoms related to Bile Duct Disease:


gastrointestinal gas, nausea and vomiting, icterus, heartburn, dyspepsia, diarrhea, constipation, abdominal pain

GenomeRNAi Phenotypes related to Bile Duct Disease according to GeneCards Suite gene sharing:

25 (show all 37)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-102 9.99 SLC51B
2 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.99 NR1I2
3 Increased shRNA abundance (Z-score > 2) GR00366-A-107 9.99 ABCC3
4 Increased shRNA abundance (Z-score > 2) GR00366-A-108 9.99 SLC51B
5 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.99 SLC51B
6 Increased shRNA abundance (Z-score > 2) GR00366-A-114 9.99 NR1I2
7 Increased shRNA abundance (Z-score > 2) GR00366-A-128 9.99 GGT2
8 Increased shRNA abundance (Z-score > 2) GR00366-A-130 9.99 ABCC3 GGT1 GGT2
9 Increased shRNA abundance (Z-score > 2) GR00366-A-131 9.99 GGT2
10 Increased shRNA abundance (Z-score > 2) GR00366-A-135 9.99 NR1I2
11 Increased shRNA abundance (Z-score > 2) GR00366-A-140 9.99 NR1I2
12 Increased shRNA abundance (Z-score > 2) GR00366-A-143 9.99 ABCB11 ABCC3 GGT1 GGT2
13 Increased shRNA abundance (Z-score > 2) GR00366-A-146 9.99 ABCC3
14 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.99 SLC10A2 SLC51B
15 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.99 SLC51B
16 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.99 NR1I2
17 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.99 GGT1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-172 9.99 NR1I2
19 Increased shRNA abundance (Z-score > 2) GR00366-A-174 9.99 ABCC3
20 Increased shRNA abundance (Z-score > 2) GR00366-A-176 9.99 ABCC3 SLC51B
21 Increased shRNA abundance (Z-score > 2) GR00366-A-189 9.99 SLC10A2
22 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.99 NR1I2
23 Increased shRNA abundance (Z-score > 2) GR00366-A-2 9.99 SLC51B
24 Increased shRNA abundance (Z-score > 2) GR00366-A-208 9.99 ABCC3
25 Increased shRNA abundance (Z-score > 2) GR00366-A-23 9.99 ABCB11
26 Increased shRNA abundance (Z-score > 2) GR00366-A-24 9.99 GGT2
27 Increased shRNA abundance (Z-score > 2) GR00366-A-39 9.99 SLC51B
28 Increased shRNA abundance (Z-score > 2) GR00366-A-45 9.99 SLC10A2
29 Increased shRNA abundance (Z-score > 2) GR00366-A-54 9.99 ABCB11
30 Increased shRNA abundance (Z-score > 2) GR00366-A-6 9.99 SLC10A2
31 Increased shRNA abundance (Z-score > 2) GR00366-A-7 9.99 GGT1 GGT2
32 Increased shRNA abundance (Z-score > 2) GR00366-A-79 9.99 SLC51B
33 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.99 SLC10A2
34 Increased shRNA abundance (Z-score > 2) GR00366-A-88 9.99 ABCB11
35 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.99 ABCB11
36 Increased shRNA abundance (Z-score > 2) GR00366-A-90 9.99 NR1I2 SLC10A2 SLC51B
37 Increased shRNA abundance (Z-score > 2) GR00366-A-96 9.99 SLC51B

MGI Mouse Phenotypes related to Bile Duct Disease:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.83 NR1I2 ABCB11 SLC10A2 ABCB4 SLC25A13 ABCC2
2 digestive/alimentary MP:0005381 9.7 NR1H4 SLC10A2 ABCB4 ABCC4 ALB CYP7A1
3 liver/biliary system MP:0005370 9.4 NR1I2 ABCB11 SLC10A2 ABCB4 SLC25A13 ABCC2
Sources

Drugs & Therapeutics for Bile Duct Disease

About this section

Drugs for Bile Duct Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 381)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vancomycin Approved Phase 4,Phase 3,Phase 1 1404-90-6 14969 441141
2
Etomidate Approved Phase 4 33125-97-2 667484 36339
3
Hydrocortisone Approved, Vet_approved Phase 4 50-23-7 657311 5754
4
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
5
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 2 2078-54-8 4943
6
Ursodeoxycholic acid Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 128-13-2 31401
7
Pancrelipase Approved, Investigational Phase 4,Phase 2,Phase 1 53608-75-6
8
Morphine Approved, Investigational Phase 4,Phase 2 57-27-2 5288826
9
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
10
Secretin Approved, Investigational Phase 4 108153-74-8
11
Meloxicam Approved, Vet_approved Phase 4 71125-38-7 54677470 5281106
12
Metronidazole Approved Phase 4,Phase 2,Phase 3,Phase 1 443-48-1 4173
13
Meperidine Approved Phase 4 57-42-1 4058
14
Ceftriaxone Approved Phase 4,Phase 2 73384-59-5 5479530 5361919
15
chenodeoxycholic acid Approved Phase 4,Phase 3,Phase 2,Early Phase 1 474-25-9 10133
16
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
17
Ofloxacin Approved Phase 4 82419-36-1 4583
18 Pinaverium Approved Phase 4 59995-65-2
19
Abatacept Approved Phase 4 332348-12-6 10237
20
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
21
Sorbitol Approved Phase 4 50-70-4 5780
22
Choline Approved, Nutraceutical Phase 4 62-49-7 305
23 Coconut Approved, Nutraceutical Phase 4
24 Tocopherol Approved, Investigational, Nutraceutical Phase 4
25
Vitamin E Approved, Nutraceutical, Vet_approved Phase 4 59-02-9 14985
26
Butyric Acid Experimental, Investigational Phase 4 107-92-6 264
27 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
28 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
29 Adjuvants, Anesthesia Phase 4,Phase 3
30 Anesthetics Phase 4,Phase 3,Phase 2
31 Anesthetics, General Phase 4,Phase 2
32 Anesthetics, Intravenous Phase 4,Phase 2
33 Anti-Anxiety Agents Phase 4,Phase 3
34 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 1,Phase 2
35 Central Nervous System Depressants Phase 4,Phase 3,Phase 2
36 Cortisol succinate Phase 4
37 GABA Agents Phase 4,Phase 3
38 GABA Modulators Phase 4
39 Hydrocortisone 17-butyrate 21-propionate Phase 4
40 Hydrocortisone acetate Phase 4
41 Hydrocortisone-17-butyrate Phase 4
42 Hypnotics and Sedatives Phase 4,Phase 2
43 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
44 Psychotropic Drugs Phase 4,Phase 3,Phase 2
45 Tranquilizing Agents Phase 4,Phase 3,Phase 2
46 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
47 Gastrointestinal Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
48 Hypolipidemic Agents Phase 4,Phase 3,Phase 2,Phase 1
49 Lipid Regulating Agents Phase 4,Phase 3,Phase 2,Phase 1
50 Nootropic Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 514)

# Name Status NCT ID Phase Drugs
1 Effect and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis Patients Unknown status NCT02605213 Phase 4 Vancomycin;Placebo
2 Endoscopic Treatment of Difficult Bile Duct Stones: Spyglass + EHL x Balloon Dilation of the Papilla Unknown status NCT02703077 Phase 4
3 Winged Perimeter Versus Traditional Plastic Biliary Stent for Malignant Bile Duct Obstruction Unknown status NCT01514214 Phase 4
4 Uncovered Self-expandable Metal Stent Versus Double Layer Plastic Stent for Malignant Hilar Stricture Unknown status NCT01125865 Phase 4
5 Effects of Etomidate on Postoperative Circadian Rhythm Changes of Salivary Cortisol in Children Unknown status NCT02013986 Phase 4 etomidate;midazolam;propofol
6 Efficacy and Safety of S-adenosyl-l-methionine in Treatment of Alcoholic Hepatitis With Cholestasis Unknown status NCT02024295 Phase 4 Ademethionine;Polyene Phosphatidyl choline;Ademethionine
7 Efficacy and Safety of S-adenosyl-L-methionine in Treatment of Chronic Hepatitis B Patients With Cholestasis Unknown status NCT01998620 Phase 4 Ademetionine 2;Ademetionine 1;Ademetionine 3
8 Additional Effects of Perioperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy Unknown status NCT01969110 Phase 4
9 Effects of Preoperative Immunonutrition in Patients Undergoing Hepatectomy Unknown status NCT01256047 Phase 4
10 The Usefulness of Endoscopic Ultrasound-guided Biliary Drainage With a Newly Designed Hybrid Metallic Stent Completed NCT01862198 Phase 4
11 A Study of Serial Magnetic Resonance Cholangiopancreatography (MRCP) Following Morphine-neostigmine and Secretin Provocation in Healthy Volunteers Completed NCT01134848 Phase 4 Morphine;Neostigmine;0.9% saline;Secretin;0.9% saline
12 Clinical Study About the Role of COX-2 Inhibitor in Liver Cirrhosis With Biliary Atresia Completed NCT02298218 Phase 4 Meloxicam
13 DGT Versus TPS in Patients With Initial PD Cannulation by Chance; Prospective Multi-center Study Completed NCT01744847 Phase 4
14 Etomidate vs. Midazolam for Sedation During ERCP Completed NCT02027311 Phase 4 Etomidate;Midazolam;Meperidine
15 Preventing Cholestasis Using SMOFLipid® Completed NCT01585935 Phase 4 SMOFLIPID;INTRALIPID
16 Effectiveness of S-adenosyl-L-methionine in Patients With Primary Biliary Cirrhosis Completed NCT02557360 Phase 4
17 Ursofalk Tablets (500 mg) Versus Ursofalk Capsules (250 mg) in the Treatment of Primary Biliary Cirrhosis Completed NCT01510860 Phase 4 UDCA (Ursodeoxycholic acid);UDCA (Ursodeoxycholic acid)
18 Effects of Preoperative Immunonutrition in Patients Undergoing Pancreaticoduodenectomy Completed NCT01256034 Phase 4
19 Comparing Covered Self-expandable Metallic Stent (SEMS) Above/Across the Sphincter of Oddi Completed NCT01041612 Phase 4
20 Biliary Metal Stent Study: Metal Stents for Management of Distal Malignant Biliary Obstruction Completed NCT00280709 Phase 4
21 Antibiotics to Decrease Post ERCP Cholangitis Recruiting NCT03087656 Phase 4 Ceftriaxone;Levofloxacin
22 WallFlex Biliary Fully Covered (FC) Chronic Pancreatitis Study Recruiting NCT01543256 Phase 4
23 Pinaverium Bromide in Post-cholecystectomy Sphincter of Oddi Dysfunction Recruiting NCT02833103 Phase 4 Danshu Capsules;Pinaverium Bromide
24 Phase 4 Study of Obeticholic Acid Evaluating Clinical Outcomes in Patients With Primary Biliary Cholangitis Recruiting NCT02308111 Phase 4 Obeticholic Acid (OCA);Placebo
25 A Pilot Study to Characterize Bile Acid Metabolism and Dysbiosis in Primary Sclerosing Cholangitis Active, not recruiting NCT02464020 Phase 4 Vancomycin
26 Study of Abatacept (Orencia) to Treat Primary Biliary Cirrhosis Active, not recruiting NCT02078882 Phase 4
27 Cyclooxygenase-2 Inhibitor for Adjuvant Anticancer Effect in Patients With Biliary-pancreas Cancer Enrolling by invitation NCT01111591 Phase 4 Cox2 inhibitor (Celecoxib)
28 A Trial of 18-22mg/kg/d Ursodeoxycholic in Refractory Primary Biliary Cholangitis Not yet recruiting NCT03345589 Phase 4 18-22mg/kg/d Ursodeoxycholic;13-15mg/kg/d Ursodeoxycholic
29 Low Dose Fat for the Prevention of Liver Disease in Babies With Gastrointestinal Disorders Terminated NCT01373918 Phase 4 Intralipid;Intralipid
30 Reduction of Neonatal Parenteral Nutrition Associated Cholestasis Through Lipid Emulsions Terminated NCT02633384 Phase 4
31 The INFECIR-2 Albumin Prevention Study Terminated NCT02034279 Phase 4 Albumin
32 Compare the Knob-tipped Knife With the Needle Knife in Difficult Biliary Cannulation Unknown status NCT01745978 Phase 3
33 RCT of Steroids Following Kasai Portoenterostomy for Biliary Atresia. Unknown status NCT00539565 Phase 3 prednisolone;placebo
34 Minimization of IntraLipid Versus Omegaven Unknown status NCT01247012 Phase 2, Phase 3
35 Probiotics in Patients With Primary Sclerosing Cholangitis Unknown status NCT00161148 Phase 3 Probiotics
36 Comparison of Endoscopic Radiofrequency Ablation Versus Photodynamic Therapy for Inoperable Cholangiocarcinoma Unknown status NCT01739465 Phase 2, Phase 3
37 Short-term Stenting Versus Balloon Dilatation for Dominant Strictures in Primary Sclerosing Cholangitis Unknown status NCT01398917 Phase 3
38 Early Enteral Feeding After Pylorus Preserving Pancreatoduodenectomy Unknown status NCT00809081 Phase 3
39 Newly Designed Fully Covered Metal Stent for the Benign Biliary Stricture Completed NCT00945516 Phase 3
40 Drotaverine Hydrochloride Versus Hyoscine-N-butylbromide for Duodenal Antimotility During Endoscopic Retrograde Cholangiopancreatography (ERCP) Completed NCT00731198 Phase 3 Drotaverine hydrochloride;Hyoscine-N-butylbromide
41 Digital SpyGlass Confirmed Common Bile Duct Stones Clearance Without Fluoroscopy Completed NCT02967926 Phase 3
42 Duloxetine in Patients With Suspected Functional Pancreatic/Biliary Pain (Sphincter of Oddi Dysfunction) Completed NCT00471315 Phase 3 Duloxetine
43 Effectiveness of Multicomponent Lipid Emulsion in Preterm Infants Requiring Parenteral Nutrition Completed NCT02663453 Phase 3 multicomponent lipid emulsion;pure soybean oil lipid emulsion
44 Clinical Outcomes of EUS-guided Biliary Drainage Using Partially or Fully Covered Metallic Stents Completed NCT02114320 Phase 3
45 Ursodiol for Treating Parenteral Nutrition Associated Cholestasis in Neonates Completed NCT00846963 Phase 2, Phase 3 Ursodiol;placebo
46 Efficacy and Safety Study of TUDCA Compare UDCA to Treatment Chronic Cholestatic Liver Disease-PBC Completed NCT01829698 Phase 3 tauroursodeoxycholic;ursodeoxycholic acid
47 Paclitaxel Eluting Covered Metallic Stent for Unresectable Malignant Bile Duct Obstruction Completed NCT00453076 Phase 3
48 A Study of the WallFlexâ„¢ Biliary Fully-covered Stent for the Palliative Treatment of Malignant Bile Duct Obstruction Completed NCT00433771 Phase 3
49 Trial of High-dose Urso in Primary Sclerosing Cholangitis Completed NCT00059202 Phase 2, Phase 3 Ursodeoxycholic Acid
50 Ursodeoxycholic Acid in the Treatment of Intrahepatic Cholestasis of Pregnancy Completed NCT01576458 Phase 3 ursodeoxycholic acid;Placebo

Search NIH Clinical Center for Bile Duct Disease

Cochrane evidence based reviews: bile duct diseases

Sources

Genetic Tests for Bile Duct Disease

About this section
Sources

Anatomical Context for Bile Duct Disease

About this section

MalaCards organs/tissues related to Bile Duct Disease:

38
Liver, Lung, Kidney, Pancreas, Small Intestine, Testes, Breast
Sources

Publications for Bile Duct Disease

About this section

Articles related to Bile Duct Disease:

(show all 18)
# Title Authors Year
1
Gallbladder and bile duct disease in Cystic Fibrosis. ( 28986023 )
2017
2
Comparative MRI analysis of morphologic patterns of bile duct disease in IgG4-related systemic disease versus primary sclerosing cholangitis. ( 24555589 )
2014
3
CHOLANGIOSCOPY IN BILE DUCT DISEASE: a case series. ( 25296087 )
2014
4
Echinococcosis mimicking autoimmune or malignant bile duct disease. ( 24022203 )
2013
5
Peripheral intrahepatic cholangiocarcinoma occurring in patients without cirrhosis or chronic bile duct diseases: epidemiology and histopathology of distant nontumoral liver in 57 White patients. ( 23085575 )
2013
6
Single-operator cholangioscopy in patients requiring evaluation of bile duct disease or therapy of biliary stones (with videos). ( 21762903 )
2011
7
Biliary cytokeratin expression but not CD56 (N-CAM) expression aids in the differential diagnosis of non-neoplastic bile duct diseases. ( 20538416 )
2010
8
Expression and localization of ecto-nucleotide pyrophosphatase/phosphodiesterase I-1 (E-NPP1/PC-1) and -3 (E- NPP3/CD203c/PD-Ibeta/B10/gp130(RB13-6)) in inflammatory and neoplastic bile duct diseases. ( 15072822 )
2004
9
Treatment of extrahepatic bile duct disease in infancy and early childhood. ( 11847446 )
2002
10
New approach in diagnosis of bile duct disease with ultrasound and magnetic resonance imaging. ( 28976650 )
1998
11
Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period. ( 8201224 )
1994
12
Rejection of murine congenic bile ducts: a model for immune-mediated bile duct disease. ( 1537528 )
1992
13
Bile duct disease: prospective comparison of ERCP, CT, and fat suppression MRI. ( 1426853 )
1992
14
Primary sclerosing cholangitis, a vanishing bile duct disease. ( 3658059 )
1987
15
Radiomanometry in the diagnosis of common bile duct disease. ( 4445925 )
1974
16
Radiomanometry, flow rates, and cholangiography in the evaluation of common bile duct disease. A study of 220 cases. ( 5058873 )
1972
17
The incidence of common bile duct disease following surgical exploration. ( 14352652 )
1955
18
Gallbladder and bile duct disease. ( 14392255 )
1955
Sources

Variations for Bile Duct Disease

About this section
Sources

Expression for Bile Duct Disease

About this section
Search GEO for disease gene expression data for Bile Duct Disease.
Sources

Pathways for Bile Duct Disease

About this section

Pathways related to Bile Duct Disease according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Metabolism 62
Show member pathways
 13.93 ABCB11 ABCB4 ABCC3 ALB CYP7A1 CYP8B1
2
Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds 62
Show member pathways
 13.24 ABCB4 ABCC2 ABCC3 ABCC4 ALB ATP8B1
3
Synthesis of bile acids and bile salts 62
Show member pathways
 12.15 ABCB11 ABCC3 ALB CYP7A1 CYP8B1 NR1H4
4
NRF2 pathway 1
11.99 ABCC2 ABCC3 ABCC4 GGT1 GGT2
5
Hepatic ABC Transporters 60
Show member pathways
 11.9 ABCB11 ABCB4 ABCC2 SLC10A1 SLCO1A2
6
Bile secretion 36
11.75 ABCB11 ABCB4 ABCC2 ABCC3 ABCC4 CYP7A1
7
Statin Pathway - Generalized, Pharmacokinetics 57
Show member pathways
 11.73 ABCB11 ABCC2 ABCC4 SLCO1A2
8
Acetaminophen Pathway (therapeutic doses), Pharmacokinetics 57
Show member pathways
 11.62 ABCC2 ABCC3 ABCC4
9
Antifolate resistance 36
11.19 ABCC2 ABCC3 ABCC4
10
Farnesoid X Receptor Pathway 1
11.08 ABCB11 ABCB4 CYP7A1 CYP8B1 NR1H4 SLC10A1
11
Photodynamic therapy-induced NFE2L2 (NRF2) survival signaling 1
11.07 ABCC2 ABCC3 ABCC4
12
Methotrexate Pathway, Pharmacokinetics 57
Show member pathways
 10.97 ABCC2 ABCC3 ABCC4 SLCO1A2
13
Aflatoxin activation and detoxification 62
10.95 GGT1 GGT2
14
Lamivudine Pathway, Pharmacokinetics/Pharmacodynamics 57
10.91 ABCC2 ABCC3 ABCC4
15
Drug Induction of Bile Acid Pathway 1
10.84 ABCB11 ABCC2 ABCC3 ABCC4 CYP7A1 NR1H4
16
Nuclear Receptors in Lipid Metabolism and Toxicity 1
10.77 ABCB11 ABCB4 ABCC2 ABCC3 CYP7A1 CYP8B1
17
Etoposide Pathway, Pharmacokinetics/Pharmacodynamics 57
10.75 ABCC3 NR1I2
18
Taxane Pathway, Pharmacokinetics 57
10.67 ABCC2 NR1I2
19
Vinka Alkaloid Pathway, Pharmacokinetics 57
10.54 ABCC2 ABCC3
Sources

GO Terms for Bile Duct Disease

About this section

Cellular components related to Bile Duct Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.65 ABCB11 ABCB4 ABCC2 ABCC3 ABCC4 ATP8B1
2 apical plasma membrane GO:0016324 9.62 ABCB4 ABCC2 ATP8B1 SLC10A2
3 basolateral plasma membrane GO:0016323 9.56 ABCC3 ABCC4 SLC10A1 SLC51B
4 brush border membrane GO:0031526 9.33 ABCB4 ABCC2 ATP8B1
5 intercellular canaliculus GO:0046581 8.8 ABCB11 ABCB4 ABCC2
6 integral component of membrane GO:0016021 10.18 ABCB11 ABCB4 ABCC2 ABCC3 ABCC4 ATP8B1

Biological processes related to Bile Duct Disease according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 transmembrane transport GO:0055085 9.65 ABCB11 ABCB4 ABCC2 ABCC3 ABCC4 SLC10A1
2 bile acid biosynthetic process GO:0006699 9.61 ABCB11 CYP7A1 CYP8B1
3 phospholipid translocation GO:0045332 9.58 ABCB4 ATP8B1
4 organic anion transport GO:0015711 9.58 ABCC2 SLCO1A2
5 xenobiotic transport GO:0042908 9.58 ABCB4 ABCC3 NR1I2
6 response to glucagon GO:0033762 9.57 ABCB4 ABCC2
7 bile acid metabolic process GO:0008206 9.56 ATP8B1 NR1H4
8 drug transmembrane transport GO:0006855 9.56 ABCB4 ABCC2 ABCC3 ATP8B1
9 glutathione catabolic process GO:0006751 9.55 GGT1 GGT2
10 zymogen activation GO:0031638 9.54 GGT1 GGT2
11 leukotriene D4 biosynthetic process GO:1901750 9.52 GGT1 GGT2
12 bile acid secretion GO:0032782 9.51 ABCB4 SLC51B
13 canalicular bile acid transport GO:0015722 9.5 ABCB11 ABCC2 ABCC3
14 response to antineoplastic agent GO:0097327 9.49 ABCB4 ABCC2
15 drug export GO:0046618 9.48 ABCB4 NR1I2
16 regulation of bile acid biosynthetic process GO:0070857 9.46 CYP7A1 NR1H4
17 ATP hydrolysis coupled anion transmembrane transport GO:0099133 9.46 ABCB11 ABCC2 ABCC3 ABCC4
18 bile acid and bile salt transport GO:0015721 9.28 ABCB11 ABCC3 ALB ATP8B1 NR1H4 SLC10A1
19 transport GO:0006810 10.11 ABCB11 ABCB4 ABCC2 ABCC3 ABCC4 ATP8B1

Molecular functions related to Bile Duct Disease according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 transporter activity GO:0005215 9.71 ABCB11 ABCC2 ABCC3 SLC25A13
2 ATPase activity GO:0016887 9.65 ABCB11 ABCB4 ABCC2 ABCC3 ABCC4
3 organic anion transmembrane transporter activity GO:0008514 9.5 ABCC2 ABCC3 SLCO1A2
4 glutathione hydrolase activity GO:0036374 9.49 GGT1 GGT2
5 thyroid hormone receptor activity GO:0004887 9.48 NR1H4 NR1I2
6 xenobiotic transmembrane transporting ATPase activity GO:0008559 9.46 ABCB4 ABCC3
7 bile acid:sodium symporter activity GO:0008508 9.43 SLC10A1 SLC10A2
8 bile acid-exporting ATPase activity GO:0015432 9.37 ABCB11 ABCC3
9 bile acid transmembrane transporter activity GO:0015125 9.33 SLC10A1 SLC51B SLCO1A2
10 ATPase-coupled anion transmembrane transporter activity GO:0043225 9.13 ABCC2 ABCC3 ABCC4
11 ATPase activity, coupled to transmembrane movement of substances GO:0042626 9.02 ABCB11 ABCB4 ABCC2 ABCC3 ABCC4
Sources

Sources for Bile Duct Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....